An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 6, 2015, Pages 926-931.e1

  Chen, Justin R ^a   Buchmiller, Brett L ^a   Khan, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aspirin desensitization; Aspirin exacerbated respiratory disease; Asthma; Chronic rhinosinusitis; Nasal polyps

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHRONIC RHINOSINUSITIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DESENSITIZATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EXPOSURE; FEMALE; HOURLY DOSE ESCALATION ASPIRIN DESENSITIZATION THERAPY; HUMAN; INTUBATION; MAJOR CLINICAL STUDY; MALE; NASOOCULAR HYPERREACTIVITY; NOSE POLYP; PATIENT SAFETY; TREATMENT DURATION; TREATMENT INDICATION; BREATHING DISORDER; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG HYPERSENSITIVITY; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATION DISORDERS;

EID: 84946410922     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.06.013     Document Type: Article

References (22)

1. Samter M., Beers R.F. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968, 68:975-983.
2. Szczeklik A., Gryglewski R.J., Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977, 60:276-284.
3. Stevenson D.D., Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006, 118:773-786.
4. Stevenson D.D., Hankammer M.A., Mathison D.A., Christiansen S.C., Simon R.A. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996, 98:751-758.
5. Berges-Gimeno M.P., Simon R.A., Stevenson D.D. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003, 111:180-186.
6. McFadden E.A., Woodson B.T., Fink J.N., Toohill R.J. Surgical treatment of aspirin triad sinusitis. Am J Rhinol 1997, 11:263-270.
7. Stevenson D.D., Simon R.A. Selection of patients for aspirin desenzitization treatment. J Allergy Clin Immunol 2006, 118:801-804.
8. Macy E., Bernstein J.A., Castells M.C., Gawchik S.M., Lee T.H., Settipane R.A., et al. Aspirin challenge and desensitization for aspirin exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007, 98:172-174.
9. Lee R.U., Stevenson D.D. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011, 3:3-10.
10. White A., Ludington E., Mehra P., Stevenson D.D., Simon R.A. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006, 97:688-693.
11. White A.A., Stevenson D.D., Simon R.A. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005, 95:330-335.
12. Stevenson D.D., Simon R.A., Mathison D.A., Christiansen S.C. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000, 85:477-482.
13. Hope A.P., Woessner K.A., Simon R.A., Stevenson D.D. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009, 123:406-410.
14. Durson A.B., Woessner K.A., Simon R.A., Karasoy D., Stevenson D.D. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008, 100:420-425.
15. Lee R.U., White A.A., Ding D., Dursun A.B., Woessner K.M., Simon R.A., et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010, 105:130-135.
16. Williams A.N., Simon R.A., Woessner K.M., Stevenson D.D. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007, 120:273-277.
17. Cox L., Larenas-Linnemann D., Lockey R.F., Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010, 125:569-574. e7. IV.
18. Bernstein D.I., Wanner M., Borish L., Liss G.M. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004, 113:1129-1136. III.
19. White A.A., Stevenson D.D., Woessner K.M., Simon R.A. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc 2013, 34:138-142.
20. 2: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015, 135:245-252.
21. White A.A., Bosso J.V., Stevenson D.D. The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 2013, 34:378-382.
22. Świerczyńska-Krepa M., Sanak M., Bochenek G., Strek P., Ćmiel A., Gielicz A., et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014, 134:883-890.